Phenoxypropazine Explained

Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.[1] [2] [3] [4] [5]

See also

Notes and References

  1. LEAHY MR, ROSE JT, PLOWMAN R . A preliminary study of phenoxypropazine in the treatment of depression . The American Journal of Psychiatry . 119 . 10. 986–7 . April 1963 . 13928824 . 10.1176/ajp.119.10.986 .
  2. IMLAH NW . Preliminary report on phenoxypropazine . The American Journal of Psychiatry . 119 . 11. 1091–2 . May 1963 . 13956423 . 10.1176/ajp.119.11.1091 .
  3. ROSE JT, LEAHY MR, PLOWMAN R . A comparison of phenoxypropazine and amitriptyline in depression . The American Journal of Psychiatry . 120 . 4. 393–5 . October 1963 . 14069469 . 10.1176/ajp.120.4.393 .
  4. ROSE JT . Phenoxypropazine and chlordiazepoxide in depression . The American Journal of Psychiatry . 120 . 9. 899–900 . March 1964 . 14129290 . 10.1176/ajp.120.9.899 .
  5. MCWHINNEY IR, MORRELL DC . Treatment of mild endogenous depression with a monoamine oxidase inhibitor: a controlled trial in general practice . The Journal of the College of General Practitioners . 9 . 95–9 . January 1965 . 1 . 14254271 . 1878242 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Phenoxypropazine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.